Table 1.

Clinical and treatment characteristics of all 98 sites of relapsed, refractory MCL treated with consolidative LDRT and associations with CR

VariableNo. of sites (%)CR, univariateCR, multivariable
HR (95% CI)P*HR (95% CI)P*
Site
 Soft tissue63 (64)1.80 (1.12-2.90).0151.79 (1.11-2.89).018
 Non–soft tissue
  Nodal22 (22)
  GI7 (7)
  Orbit3 (3)
  Mucosal2 (2)
  Bone1 (1)
No. of fractions
 2, ×2 Gy72 (73)1.17 (0.68-2.02).566
 1, ×4 Gy26 (27)
RT modality
 Photons65 (66)0.68 (0.43-1.09).109
 Nonphotons
  Electrons32 (33)
  Orthovoltage1 (1)
Diagnosis to LDRT
 ≥36 mo36 (37)0.73 (0.46-1.18).201
 <36 mo62 (63)
Lesion size
 ≥3 cm47 (48)0.76 (0.48–1.21).2450.69 (0.43-1.10).120
 <3 cm51 (52)
Histology
 Blastoid27 (28)0.78 (0.45-1.35).374
 Nonblastoid71 (72)
Chemorefractory
 Yes, to ongoing74 (76)1.41 (0.86-2.32).1751.40 (0.84-2.32).194
 No, to ongoing24 (24)
Ibrutinib-refractory
 Yes80 (82)1.10 (0.65-1.88).716
 No18 (18)
Prior chemo
 >5 courses33 (34)0.97 (0.61-1.55).906
 ≤5 courses65 (66)
Prior SCT
 Yes42 (43)0.92 (0.58-1.44).706
 No56 (57)
Concurrent chemo
 Yes74 (76)1.26 (0.75-2.11).379
 No24 (24)
Post-LDRT chemo
 Yes79 (81)0.99 (0.58-1.68).963
 No19 (19)
  • chemo, chemotherapy; CI, confidence interval; GI, gastrointestinal; HR, hazard ratio; SCT, stem cell transplantation.

  • * Cox proportional hazards for univariate and multivariable analyses of associations with outcomes.